| Overview |
| bs-12358R-APC |
| YKL39/CHI3L2 Polyclonal Antibody, APC Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Specifications |
| APC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human YKL39/CHI3L2 |
| 121-220/390 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 7690 |
| Secreted |
| CH3L2_HUMAN; CHI3L2; Chitinase 3 like 2; Chitinase-3-like protein 2; Chondrocyte protein 39; OTTHUMP00000014028; YKL 39; YKL-39; YKL39. |
| YKL-39 is a 390 amino acid cartilage protein that belongs to the chitinase family of chitin-fragmenting hydrolases. Highly expressed in chondrocytes (cartilage cells) and synoviocytes (fibroblastic cells that line joint cavities), YKL-39 binds glycan structures with high affinity. Although related to bacterial chitinases, YKL-39 lacks the characteristic glutamate active site and, thus, does not have enzymatic chitinase activity. Patients affected with rheumatoid arthritis (RA) have autoimmunity against YKL-39, suggesting that YKL-39 is involved in osteoarthritic and/or rheumatoid joint disease. Additionally, YKL-39 is upregulated in early degenerative cartilage diseases (such as RA) and may be a marker of chondrocyte activation in these autoimmune conditions. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz